Citations

Clear

6273 citation(s) found for "To, Andrew".

Cardiac Risk of Noncardiac Surgery after Percutaneous Coronary Intervention with Drug-eluting Stents
Rabbitts, Jennifer A. , Nuttall, Gregory A. , Brown, Michael J., Hanson, Andrew C. , Oliver, William C., Holmes, David R. , Rihal, Charanjit S. , Rihal, Charanjit S.

Mayo Clinic

Anesthesiology | January 27, 2010 | Volume: 109 | Issue: 4 | Pages: 596-604

10.1097/aln.0b013e318186de1c | PMID 18813037 Get It

Background The American College of Cardiology released a scientific advisory that included a recommendation to delay elective of noncardiac surgery (NCS) for 1 yr after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES). Methods This single-center, retrospective study examined the risk for complications of NCS performed within 2 yr after DES placement and examined whether this risk changed based on the time between procedures. The primary endpoint was major adverse cardiac events (MACEs) during the hospitalization for NCS. Bleeding events were analyzed as a secondary endpoint. Results From April 22, 2003, to December 31, 2006, a total of 520 patients underwent NCS within 2 yr after PCI with a DES at Mayo Clinic. The majority, 84%, of the DES placed were Cypher stents. The frequency of MACE was not found to be significantly associated with the time between PCI and NCS (rate of MACEs 6.4, 5.7, 5.9, and 3.3% at 0-90, 91-180, 181-365, and 366-730 days after PCI with DES, respectively; P = 0.727 for comparison across groups). Characteristics found to be associated with MACEs in univariate analysis were advanced age (P = 0.031), emergent NCS (P = 0.006), shock at time of PCI (P = 0.035), previous history of myocardial infarction (P = 0.046), and continuation of a thienopyridine (ticlopidine or clopidogrel) into the preoperative period (P = 0.040). The rate of transfusion did not seem to be associated with antiplatelet therapy use. Conclusions The risk of MACEs with NCS after DES placement was not significantly associated with time from stenting to surgery, but observed rates of MACEs were lowest after 1 yr.
Time and Cardiac Risk of Surgery after Bare-metal Stent Percutaneous Coronary Intervention
Nuttall, Gregory A. , Brown, Michael J., Stombaugh, John W., Michon, Peter B., Hathaway, Matthew F., Lindeen, Kevin C., Hanson, Andrew C. , Schroeder, Darrell R. , Oliver, William C., Holmes, David R. , Rihal, Charanjit S. , Lindeen, Kevin C., Rihal, Charanjit S. , Schroeder, Darrell

Mayo Clinic

Anesthesiology | January 27, 2010 | Volume: 109 | Issue: 4 | Pages: 588-595

10.1097/aln.0b013e318186ddf8 | PMID 18813036 Get It

Background The duration of time that elective noncardiac surgery (NCS) should be delayed after percutaneous coronary intervention (PCI) with bare metal stents (BMSs) is unknown. Methods This large, single-center, retrospective study examined the relation between complication rate in patients with BMSs undergoing NCS and the duration of time between PCI and NCS. Primary endpoints included in-hospital major adverse cardiac events (death, myocardial infarction, stent thrombosis, or repeat revascularization with either coronary artery bypass grafting or PCI of the target vessel) and bleeding events. The relation between the events and the timing of noncardiac surgery after PCI with BMS was assessed using univariate analysis and multiple logistic regression. Results From January 1, 1990, to January 1, 2005, a total of 899 patients were identified. The frequency of major adverse cardiac events was 10.5% when NCS was performed less than 30 days after PCI with BMS, 3.8% when NCS was performed between 31 and 90 days after PCI with BMS, and 2.8% when NCS was performed more than 90 days after PCI with BMS. In univariate and multivariate analyses, a shorter time interval between PCI with BMS and noncardiac surgery was significantly associated with increased incidence of major adverse cardiac events (univariate: P < 0.001; odds ratio = 4.0; 95% confidence interval, 2.0-8.3; multivariate: P = 0.006; odds ratio = 3.2; 95% confidence interval, 1.5-6.9). Bleeding events were not associated with time between PCI with BMS and NCS or with the use of antiplatelet therapy in the week before NCS. Conclusions The incidence of major adverse cardiac events is lowest when NCS is performed at least 90 days after PCI with BMS.
Direct Diagnosis in Radiology Series.
Young, Lisa R. , Deutsch, Gail , Bowman, Andrew W.

Mayo Clinic

American Journal of Roentgenology | January 21, 2010 | Volume: 194 | Issue: 2 | Pages: W238-W238

10.2214/ajr.09.3385 | PMID 20028928 Get It

2007 Universal Myocardial Infarction Definition Change Criteria for Risk Stratification by Use of a High-Sensitivity Cardiac Troponin I Assay
Kavsak, Peter A. , Ko, Dennis T. , MacRae, Andrew R., Jaffe, Allan S. , Wang, Xuesong , Jaffe, Allan S. , Kavsak, Peter

Mayo Clinic

Clinical Chemistry | January 14, 2010 | Volume: 56 | Issue: 3 | Pages: 487-489

10.1373/clinchem.2009.136689 | PMID 20075178 Get It

ESR1/SYNE1 Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study
Rossing, Mary Anne, Cushing‐Haugen, Kara L. , Chen, Chu , Berg, David J. Van Den, Wu, Anna H. , Pike, Malcolm C. , Ness, Roberta B., Moysich, Kirsten B., Chenevix‐Trench, Georgia , Beesley, Jonathan, Webb, Penelope M. , Chang‐Claude, Jenny, Wang‐Gohrke, Shan , Goodman, Marc T. , Lurie, Galina, Thompson, Pamela J., Carney, Michael E., Høgdall, Estrid , Kjær, Susanne K. , Høgdall, Claus , Goode, Ellen L. , Cunningham, Julie M. , Vierkant, Robert A. , Moorman, Patricia G. , Schildkraut, Joellen M. , Palmieri, Rachel T., Terry, Kathryn L. , García‐Closas, Montserrat , Lissowska, Jolanta , Song, Honglin , Shah, Mitul , Perkins, Barbara, McGuire, Valerie , Whittemore, Alice S. , Cioccio, Richard A. Di, Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Group, The Australian Ovarian Cancer Study Management, Cancer), The Australian Cancer Study (Ovarian, Pearce, Celeste Leigh, Weber, Rachel Palmieri , Doherty, Jennifer A. , Fridley, Brooke L. , Berchuck, Andrew , Cramer, Daniel W. , Yang, Hannah , Chanock, Stephen Jacob , Pharoah, Paul D.P. , Gentry‐Maharaj, Aleksandra , Ziogas, Argyrios , Brewster, Wendy R. , Anton‐Culver, Hoda , Group, The Australian Ovarian Cancer Study Management, Cancer), The Australian Cancer Study (Ovarian, Pearce, Celeste Leigh, Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 7, 2010 | Volume: 19 | Issue: 1 | Pages: 245-250

10.1158/1055-9965.epi-09-0729 | PMID 20056644 Get It

Abstract We genotyped 13 single nucleotide polymorphisms (SNPs) in the estrogen receptor alpha gene (ESR1) region in three population-based case-control studies of epithelial ovarian cancer conducted in the United States, comprising a total of 1,128 and 1,866 non-Hispanic white invasive cases and controls, respectively. A SNP 19 kb downstream of ESR1 (rs2295190, G-to-T change) was associated with invasive ovarian cancer risk, with a per-T-allele odds ratio (OR) of 1.24 [95% confidence interval (CI), 1.06-1.44, P = 0.006]. rs2295190 is a nonsynonymous coding SNP in a neighboring gene called spectrin repeat containing, nuclear envelope 1 (SYNE1), which is involved in nuclear organization and structural integrity, function of the Golgi apparatus, and cytokinesis. An isoform encoded by SYNE1 has been reported to be downregulated in ovarian and other cancers. rs2295190 was genotyped in an additional 12 studies through the Ovarian Cancer Association Consortium, with 5,279 invasive epithelial cases and 7,450 controls. The per-T-allele OR for this 12-study set was 1.09 (95% CI, 1.02-1.17; P = 0.017). Results for the serous subtype in the 15 combined studies were similar to those overall (n = 3,545; OR, 1.09; 95% CI, 1.01-1.18; P = 0.025), and our findings were strongest for the mucinous subtype (n = 447; OR, 1.32; 95% CI, 1.11-1.58; P = 0.002). No association was observed for the endometrioid subtype. In an additional analysis of 1,459 borderline ovarian cancer cases and 7,370 controls, rs2295190 was not associated with risk. These data provide suggestive evidence that the rs2295190 T allele, or another allele in linkage disequilibrium with it, may be associated with increased risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev; 19(1); 244–50
Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection
Rose, Jennifer B. , Naydenova, Zlatina, Bang, Andrew , Eguchi, Megumi, Sweeney, Gary , Hammond, James R. , Coe, Imogen R. , Choi, Doo‐Sup

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | December 25, 2009 | Volume: 298 | Issue: 3 | Pages: H771-H777

10.1152/ajpheart.00711.2009 | PMID 20035027 Get It

To better understand the role of equilibrative nucleoside transporters (ENT) in purine nucleoside-dependent physiology of the cardiovascular system, we investigated whether the ENT1-null mouse heart was cardioprotected in response to ischemia (coronary occlusion for 30 min followed by reperfusion for 2 h). We observed that ENT1-null mouse hearts showed significantly less myocardial infarction compared with wild-type littermates. We confirmed that isolated wild-type adult mouse cardiomyocytes express predominantly ENT1, which is primarily responsible for purine nucleoside uptake in these cells. However, ENT1-null cardiomyocytes exhibit severely impaired nucleoside transport and lack ENT1 transcript and protein expression. Adenosine receptor expression profiles and expression levels of ENT2, ENT3, and ENT4 were similar in cardiomyocytes isolated from ENT1-null adult mice compared with cardiomyocytes isolated from wild-type littermates. Moreover, small interfering RNA knockdown of ENT1 in the cardiomyocyte cell line, HL-1, mimics findings in ENT1-null cardiomyocytes. Taken together, our data demonstrate that ENT1 plays an essential role in cardioprotection, most likely due to its effects in modulating purine nucleoside-dependent signaling and that the ENT1-null mouse is a powerful model system for the study of the role of ENTs in the physiology of the cardiomyocyte.
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Lasky, Joseph A. , Mieras, Kathleen, Gabor, Edith, Schroeder, Darrell R. , Selman, Moisés , Daniels, Craig , Limper, Andrew H. , Schroeder, Darrell

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | December 10, 2009 | Volume: 181 | Issue: 6 | Pages: 604-610

10.1164/rccm.200906-0964oc | PMID 20007927 Get It

Abstract Rationale Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease. Objectives To investigate the safety and clinical effects of imatinib in patients with IPF. Methods We studied 119 patients in an investigator-initiated, multicenter, multinational, double-blind clinical trial to receive imatinib or placebo for 96 weeks. Measurements and Main Results Over 96 weeks of follow-up, imatinib did not differ significantly from placebo (log rank P = 0.89) for the primary endpoint defined as time to disease progression (10% decline in percent predicted FVC from baseline) or time to death. There was no effect of imatinib therapy on change in FVC at 48, 72, or 96 weeks (P ≥ 0.39 at all time points) or change in diffusing capacity of carbon monoxide at 48, 72, or 96 weeks (P ≥ 0.26 at all time points). Change in resting PaO2 favored imatinib therapy at 48 weeks (P = 0.005) but not at 96 weeks (P = 0.074). During the 96-week trial there were 8 deaths in the imatinib group and 10 deaths in the placebo group (log rank test P = 0.64). Thirty-five (29%) patients discontinued the study without reaching the primary endpoint (imatinib, 32%; placebo, 27%; P = 0.51). Serious adverse events (SAEs) were not more common in the imatinib group (imatinib, 18 SAEs in 17 patients; placebo, 19 SAEs in 18 patients). Conclusions In a randomized, placebo-controlled trial of patients with mild to moderate IPF followed for 96 weeks, imatinib did not affect survival or lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00131274).
Revised Tumor and Node Categorization for Rectal Cancer Based on Surveillance, Epidemiology, and End Results and Rectal Pooled Analysis Outcomes
Gunderson, Leonard L., Jessup, J. Milburn , Sargent, Daniel J. , Greene, Frederick L. , Stewart, Andrew K., Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | December 1, 2009 | Volume: 28 | Issue: 2 | Pages: 256-263

10.1200/jco.2009.23.9194 | PMID 19949015 Get It

Purpose The sixth edition of the American Joint Committee on Cancer (AJCC) rectal cancer staging subdivided stage II into IIA (T3N0) and IIB (T4N0) and stage III into IIIA (T1-2N1M0), IIIB (T3-4N1M0), and IIIC (anyTN2M0). Subsequent analyses supported revised substaging of stage III as a result of improved survival with T1-2N2 versus T3-4N2 and survival of T4N1 more similar to T3-4N2 than T3N1. The AJCC Hindgut Taskforce sought population-based validation that depth of invasion interacts with nodal status to affect survival. Methods Surveillance, Epidemiology, and End Results (SEER) population-based data from January 1992 to December 2004 for 35,829 patients with rectal cancer were compared with rectal pooled analysis data (3,791 patients). T4N0 cancers were stratified by tumors that perforate visceral peritoneum (T4a) versus tumors that invade or are adherent to adjacent organs or structures (T4b). N1 and N2 were stratified by number of positive nodes as follows: N1a/N1b (one v two to three nodes) and N2a/N2b (four to six v ≥ seven nodes). Five-year observed and relative survival rates were obtained for each TN category. Results SEER rectal cancer analyses confirm that T1-2N2 cancers have better prognosis than T3-4N2, T4bN1 have similar prognosis to T4N2, T1-2N1 have similar prognosis to T2N0/T3N0, and T1-2N2a have similar prognosis to T2N0/T3N0 (T1N2a) or T4aN0 (T2N2a). Prognosis for T4a lesions is better than T4b by N category. The number of positive nodes affects prognosis. Conclusion This SEER population-based rectal cancer analysis validates the rectal pooled analyses and supports the shift of T1-2N2 lesions from IIIC to IIIA or IIIB and T4bN1 from IIIB to IIIC. SEER outcomes support subdividing T4, N1, and N2 and revised substaging of stages II and III. Survival by TN category suggests a complex biologic interaction between depth of invasion and nodal status.